Skip to main content

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine

Department of Cardiovascular Medicine

Cardiovascular Division

Mayo Clinic

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

R. Scott Wright, MD

Since ODYSSEY Outcomes demonstrated a reduction in adverse CV outcomes—as well as a decrease in associated, all-cause mortality—in post-ACS patients, what is your view on treating to push LDL-C levels to even lower levels than the 70 mg/dL threshold?

Since ODYSSEY Outcomes demonstrated a reduction in adverse CV outcomes—as well as a decrease in associated, all-cause mortality—in post-ACS patients, what is your view on treating to push LDL-C levels to even lower levels than the 70 mg/dL threshold?

R. Scott Wright, MD

What are the risks of failing to lower LDL-C levels to AHA- or ESC Guideline-mandated thresholds?

What are the risks of failing to lower LDL-C levels to AHA- or ESC Guideline-mandated thresholds?

R. Scott Wright, MD

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?

R. Scott Wright, MD

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

R. Scott Wright, MD

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

R. Scott Wright, MD

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

R. Scott Wright, MD

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

R. Scott Wright, MD

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

R. Scott Wright, MD

What is the true incidence of statin intolerance and how do you diagnose it? And what is your approach to re-challenge and titration with other statins? And where do alirocumab and evolocumab fit into the statin intolerance treatment plan?

What is the true incidence of statin intolerance and how do you diagnose it? And what is your approach to re-challenge and titration with other statins? And where do alirocumab and evolocumab fit into the statin intolerance treatment plan?

R. Scott Wright, MD